KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Rigel Pharmaceuticals (RIGL) EPS (Weighted Average and Diluted) (2019 - 2025)

Rigel Pharmaceuticals (RIGL) has 10 years of EPS (Weighted Average and Diluted) data on record, last reported at $14.11 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) rose 1641.98% year-over-year to $14.11; the TTM value through Dec 2025 reached $19.48, up 1867.68%, while the annual FY2025 figure was $19.48, 1867.68% up from the prior year.
  • EPS (Weighted Average and Diluted) reached $14.11 in Q4 2025 per RIGL's latest filing, up from $1.46 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $14.11 in Q4 2025 and bottomed at -$3.09 in Q4 2022.
  • Average EPS (Weighted Average and Diluted) over 5 years is $0.83, with a median of -$0.06 recorded in 2021.
  • Peak YoY movement for EPS (Weighted Average and Diluted): plummeted 2107.14% in 2022, then surged 5566.67% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.14 in 2021, then crashed by 2107.14% to -$3.09 in 2022, then soared by 101.62% to $0.05 in 2023, then surged by 1520.0% to $0.81 in 2024, then soared by 1641.98% to $14.11 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were $14.11 in Q4 2025, $1.46 in Q3 2025, and $3.28 in Q2 2025.